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Abstract: The following communication summarizes the proceed-
ings of a 1-day Workshop of the International Melanoma Pathol-
ogy Study Group, which was devoted to thin melanoma. The
deﬁnitions and histologic criteria for thin melanoma were reviewed.
The principal diﬀerential diagnostic problems mentioned included
the distinction of thin melanoma from nevi, especially from nevi of
special site, irritated nevi, inﬂamed and regressing nevi, and dys-
plastic nevi. Histologic criteria for this analysis were discussed and
the importance of clinico-pathologic correlation, especially in acral
sites, was emphasized. Criteria for the minimal deﬁnition of inva-
sion were also discussed. In addition, a new technique of m-RNA
expression proﬁling with 14 genes was presented and facilitated the
distinction of thin melanomas from nevus in histologically obvious
cases. However, for particular nevi, it was not obvious why the
results indicated a malignant lesion. Despite many molecular and
other ancillary investigations, Breslow thickness remains the most
important prognostic factor in thin melanoma. The prognostic
signiﬁcance of radial (horizontal) and vertical growth phases, Clark
level, regression, and mitotic rate were also discussed. Because of
the increasing frequency of thin melanomas, there is a great need to
develop more reﬁned predictors of thin melanomas with worse
clinical outcome.
Key Words: thin melanoma, Breslow thickness, mitotic rate, growth
phase, regression, angiotropism
(Adv Anat Pathol 2016;23:24–29)
A 1-day Workshop of the International MelanomaPathology Study Group devoted to “The Pathology of
Thin Melanoma” (Table 1) was convened on November 12,
2014 in Zurich, Switzerland at University Hospital Zurich.
The goals were a general review of current knowledge on
this subject with particular reference to histologic deﬁnition
and description, nomenclature, diﬀerential diagnosis, con-
troversies peculiar to thin melanoma, predictors of out-
come, and future directions. The Workshop was organized
as interactive focus sessions as follows.
DIAGNOSIS: WHAT IS THIN MELANOMA?;
CRITERIA FOR HISTOLOGIC DIAGNOSIS;
DEFINITION OF MINIMAL INVASION; SUBTYPES
Melanoma Microinvasion
Whether a melanoma is in situ or microinvasive is
sometimes diﬃcult or impossible to judge even for experts
as illustrated by Workshop cases presented. However, it
was the view of most Workshop participants that the
presence of only a few invasive melanoma cells, still indi-
cative of the radial (horizontal) growth phase, has no sig-
niﬁcant prognostic impact and therefore might even be
disregarded. In contrast, the importance of recognizing the
progression from horizontal to vertical growth phase in
melanoma was emphasized and may be indicated by the
detection of dermal mitoses or dermal nests of melanoma
cells larger than junctional nests.
Thin Melanoma and Breslow Thickness
Dermatopathologists are increasingly confronted with
thin melanocytic lesions, and it is well established that there
has been a signiﬁcant increase in the number of thin mel-
anomas (<1.0mm in thickness) over the past 2 to 3 dec-
ades. Recent studies indicate that approximately 70% of
melanomas are classiﬁed as thin. A number of explanations
for the latter trends have been suggested, such as causative
factors, for example, increased sun exposure, more rigorous
reporting of melanoma to cancer registries, “diagnostic
drift,” and more intensive cancer screening and greater
rates of biopsy sampling of pigmented skin lesions.1 There
is continued controversy in the literature about these issues.
However, one of the best documented explanations may
potentially be attributed to increased skin cancer awareness
and skin cancer screening in many western countries. As a
result, there is mounting evidence that melanocytic lesions
are increasingly being sampled or removed at an early
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stage.2–5 As the cure rate for most thin lesions is excellent, it
is likely that these otherwise salutary trends have con-
tributed to the phenomenon of “overdiagnosis” of cancer
that is characterized by a rising incidence without a corre-
sponding increase in mortality.6 Strict criteria for diagnosis
of malignancy should be applied, and the evidence suggests
that present criteria lack the necessary speciﬁcity to reliably
discriminate between early melanomas and their simulants
(see next section) (Table 1).
DIFFERENTIAL DIAGNOSIS
Principal Diagnostic Difficulties
Thin melanomas are often diﬃcult to distinguish from
dysplastic nevi, irritated/traumatized melanocytic nevi,
inﬂamed or halo nevi or partially regressed nevi, site-spe-
ciﬁc nevi (nevi from special anatomic sites), plaque-type
Spitz tumors, and pigmented spindle cell nevi. In analogy to
macroscopy and the ABCDE rule, we have histologic signs
of malignancy (Table 2). In thin melanocytic lesions intra-
tumoral cell heterogeneity with atypical lentiginous mela-
nocytic proliferation and small and large nests of diﬀerent
atypical melanocytes suggest malignancy (Figs. 1A, B).
However, for ﬁnal diagnosis it is crucial to consider all
histologic aspects (lesional diameter, eg, banal nevi usually
<5mm vs. larger size in melanoma), symmetry, lateral
demarcation, pagetoid proliferation, degree of cytologic
atypia, mitoses, maturation, focal/diﬀuse host response).
For example, pagetoid scatter is not an explicit sign of
malignancy, as it can be observed in a variety of melano-
cytic neoplasms including acral nevi, congenital nevi, nevi
in pediatric populations, traumatized nevi, pagetoid Spitz
nevi, and pigmented spindle cell nevi.7 Quite often we
observe pagetoid inﬁltration in dysplastic nevi and are
unable to judge whether this means melanoma in situ
developing in dysplastic nevus or just irritation of a dys-
plastic nevus (Figs. 1C, D). However, because of uncer-
tainty in many lesions, the treatment is often the same with
excision of about 5mm margins.
The histologic diagnosis of melanocytic lesions is not
standardized. In addition, the consensus for diﬃcult mela-
nocytic lesions is poor even among experts. Interestingly,
general agreement on the type of surgical therapy indicated
is much better. Consequently, the Melanocytic Pathology
Assessment Tool and Hierarchy for Diagnosis (MPATH-
Dx) has been proposed. In analogy to BI-RADS (Breast
Imaging Reporting and Data System) used in breast
imaging, MPATH-Dx facilitates categorization of lesions
with diverse nomenclature into a hierarchy of standardized
management interventions.8
Melanomas on acral skin are usually diﬀerent from
melanomas developing at other anatomic sites such as the
trunk, where one often observes superﬁcial spreading
variants of melanomas. Many acral melanomas are not
obviously malignant on histologic grounds. Thin acral
melanomas often exhibit relatively little atypia, no pagetoid
spread, and few or no mitoses. Relatively large acral lesions
without nest formation and lentiginous melanocytic pro-
liferation with long coarse dendrites should raise concern
about acral melanoma. Correlation with clinical features
strongly suggesting obvious acral melanoma facilitates the
diagnosis (Figs. 2A, B)
Regression in thin melanomas can be diﬃcult to dif-
ferentiate from a scar in a nevus after trauma or previous
excision. Clinical information about localization and pre-
vious surgery is critical for a correct diagnosis. Regressed
melanomas are often more easily identiﬁed on macroscopic
grounds because of asymmetry, variegated color, and lack
of sharp demarcation. Good clinico-pathologic correlation
can facilitate proper diagnosis of regressed melanoma
(Figs. 2C, D).
Classical nevoid melanoma often shows high cell
density of small cells with hyperchromatic nuclei and rela-
tively scant cytoplasm. There is usually no maturation with
depth and mitoses are present by deﬁnition. Junctional
atypical melanocytic proliferation is usually scanty. Apart
from this classical nevoid type, another melanoma shows
superﬁcial features of superﬁcial spreading melanoma-type
melanoma, which in the superﬁcial to mid dermis change to
cells with round hyperchromatic nuclei giving an impres-
sion of maturation. The deeper cells are still distinct from
benign nevus cells but the suggestion of maturation may
lead to misdiagnosis as a benign lesion. For this phenom-
enon the term pseudo-maturation or paradoxical matura-
tion is used9,10 (Figs. 2E, F). Preliminary results suggest
that this type of nevoid melanoma has a more favorable
prognosis versus that of classical nevoid melanoma.
Gene Expression Analysis for the Distinction of
Nevi From Melanoma
Gene expression analysis by quantitative reverse
transcriptase polymerase chain reaction was presented to
diﬀerentiate benign nevi from melanoma. The genes include
PRAME (for preferentially expressed antigen in mela-
noma); a group of 5 multifunctional genes including
S100A7, S100A8, S100A9, S100A12, and PI3; a group of 8
TABLE 1. What Is Thin Melanoma?
An expression of epidermal and superﬁcial dermal involvement:
“Superﬁcial vs. deep” melanoma
An expression of evolution in time:
Early melanoma (me´lanome de´butant) vs. older melanoma
An expression of Breslow thickness:
<0.76mm
<0.85mm
r1.0mm
<1.5mm
An expression of growth phase:
Radial or horizontal growth
Vertical growth
An expression of anatomic level (Clark):
Level II (microinvasive)
Level III
Level IV
TABLE 2. Differential Diagnosis
Principal diagnostic problems
Melanoma vs. dysplastic nevus
Nevoid lentigo maligna vs. dysplastic nevus
Nevoid melanoma vs. nevus
Nested nevoid melanoma vs. nevus
Melanoma vs. pagetoid proliferations
Melanoma vs. traumatized nevus
Melanoma vs. ﬁbrosing nevus
Halo melanoma vs. halo nevus
Melanoma vs. spitzoid and pigmented spindle cell lesions
Melanoma vs. site-speciﬁc nevi
Adv Anat Pathol  Volume 23, Number 1, January 2016 Thin Melanoma
Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved. www.anatomicpathology.com | 25
Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved.
genes involved in tumor immune response signaling (IRF1,
CCL5, CXCL9, CXCL10, CD38, LCP2, PTPRC, SELL);
and 9 housekeeper genes used for normalization of the
expression data (CLTC, MRFAPI, PPP2CA, PSMA1,
RPL13A, RPL8, RPS29, SLC25A3, TXNLI). On the basis
of analysis of thousands of benign nevi and melanomas a
scoring system was developed. Most unequivocally benign
nevi have a score <2 and most obvious malignant
FIGURE 1. A–C, A 40-year-old man with SSM-type melanoma on the back. Overview (A) and higher magnification (B, C) illustrating
melanoma tumor heterogeneity with atypical lentiginous single cell proliferation, small and large nests of atypical melanocytes (A: HE,
40; inset: Melan A immunohistochemistry, 40. B: HE, 80. C: Melan A immunohistochemistry, 80). HE indicates hematoxylin
and eosin; SSM, superficial spreading melanoma.
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melanoma a score >0.11 However, cases were also descri-
bed that were not malignant on histologic grounds but the
scoring system indicated a malignant lesion. It is crucial to
mention that the above-mentioned test includes genes that
are normally expressed in benign and malignant melano-
cytic lesions. Neither speciﬁc melanocytic genes nor genes
with prognostic signiﬁcance were represented in the
analysis.
FIGURE 2. A and B, A 63-year-old man with acral melanoma right foot. A, Lentiginous melanocytic proliferation, without significant
atypia, pagetoid spread, or mitoses. A, HE 200; inset: Melan A immunohistochemistry, 200. B, Clinically clear-cut melanoma. C and D,
Melanoma with regression in the left lateral thigh. C, Histology with central dermal nevoid component, general symmetry, and features
suggesting a benign lesion (HE 40; inset: HE 250). D, Clinically the lesion is clear-cut melanoma. E, Classical nevoid melanoma
(HE 50). F, Melanoma with superficial features of SSM-type and deeper small atypical cells suggesting maturation, or so called pseudo-
maturation or paradoxical maturation (HE 200). HE indicates hematoxylin and eosin; SSM, superficial spreading melanoma.
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SPECIFIC PROBLEMS IN THIN MELANOMA:
MITOTIC ACTIVITY, AJCC/UICC GUIDELINES, etc.
Thin Melanoma and Mitotic Activity
The prognostic value of mitotic activity in melanoma is
well established. However, the inclusion of mitotic rate in the
microstaging criteria for thin melanoma in the seventh edi-
tion of AJCC and eighth edition UICC classiﬁcation,
respectively, has proved to be controversial (Table 3).
Because of the diﬃculty and uncertainty surrounding
assessment of mitotic activity in thin melanomas, many have
called for a re-examination of this issue in the microstaging
of thin melanoma. Recent NCCN guidelines in the United
States recommend that “multiple mitoses” or other risk
factors such as ulceration or lymphovascular invasion should
be present in melanomas thinner than Breslow’s original
cutoﬀ of 0.76mm for low risk, when considering a recom-
mendation for sentinel node staging.12 It is imperative that
accurate and reliable methodology for identiﬁcation and
quantiﬁcation of mitotic rate is developed. Recent studies
have evaluated appropriate tissue sampling and step sec-
tioning to optimize diagnosis of mitotic activity. According
to the study results, there is a need for 3 to 5 sections to
identify hot spots thereby increasing accuracy of mitotic rate
interpretation. Furthermore, there is a general increase in
likelihood of ﬁnding mitotically active thin melanoma with
increasing Breslow depth.13
SPECIFIC PROBLEMS IN THIN MELANOMA:
REGRESSION, LYMPHATIC INVASION, AND
ANGIOTROPISM
Regression in thin Melanoma
Regression, usually aﬀecting the radial growth phase,
is common in melanoma, particularly in thin lesions. Its
incidence among all melanoma tumor thicknesses has been
estimated at about 10% to 35% and up to 58% in mela-
nomas with thicknesses <0.75mm (Table 4). Extensive
regression (>77% of the tumor) is associated with an
adverse clinical outcome.14 Interestingly, also radial growth
phase regression is an adverse prognostic factor. In con-
trast, tumor-inﬁltrating lymphocytes representing an active
immune response may represent a form of vertical growth
phase regression and are associated with a good prog-
nosis.15–17 These seemingly conﬂicting observations may be
at least partly explained by increased vessel density, espe-
cially increased lymphatic vessel density, in areas of
regression. Furthermore lymphatic invasion by melanoma
may be detected in zones of regression. Increased vessel
density as well as lymphatic invasion by melanoma in areas
of complete regression are associated with poor clinical
outcome.15,17 However, other studies have not conﬁrmed
the latter observations.
Angiotropism and Melanoma
The propensity for melanoma to migrate along ana-
tomic structures such as nerves and skin appendages is a
common phenomenon. Barnhill and Lugassy’s experiments
have shown several years ago that melanoma cells migrate
along the external surfaces of vascular channels, without
intravasation.18,19 Their revolutionary new paradigm of
tumor spread is called extravascular migratory metastases.
Recently, in a mouse model, experiments have shown that
ultraviolet radiation induces increased rates of angiotrop-
ism of melanoma cells, extravascular migration of tumor
cells, and an increased frequency of metastasis. In thick
melanoma angiotropism is correlated with metastatic dis-
ease.20 The relevance of angiotropism in thin melanomas
requires additional study.
PREDICTORS OF OUTCOME: PROGNOSTIC
FACTORS IN THIN MELANOMA
Despite greater and greater molecular characterization
of melanoma, Breslow thickness is still among the most
powerful prognostic factors in both the AJCC and UICC
schemes (Table 5).21,22 Thin melanomas are classiﬁed as
pT1 stage with tumor thickness <1mm. Despite the
excellent prognosis of thin melanomas, 20% are associated
with metastasis and 5% are fatal.23 As a consequence of
increasing numbers of thin melanoma, these facts cannot
any longer be neglected. There is a need to identify this
subgroup with adverse clinical outcome. Breslow’s original
publication showed that all patients with tumor thickness
<0.76mm were disease free at 5 years. Nonetheless, Bre-
slow acknowledged that undoubtedly rare melanomas
<0.76mm with adverse outcome exist. For practical pur-
poses, thereafter, a threshold of 1mm was chosen to deﬁne
thin melanoma. Recent studies conﬁrm Breslow’s ﬁndings
TABLE 3. Mitotic Activity in Thin Melanoma
Breslow thickness, ulceration, and mitotic rate are interrelated
In particular, mitotic rate is closely associated with thickness and
ulceration
Mitotic rates are diﬃcult to assess in thin melanomas, as tissue is
limited
Greater sampling of tissue aides in the analysis of mitoses
There is greater uncertainty about mitoses in thin melanoma
Assessment and reproducibility of mitotic rate in thin melanoma
have not been suﬃciently studied
The use of the “hot spot” technique introduces bias, as hot spots
are uncommon
The mitotic index expressed as mitoses per mm2 may represent the
best prognostic value
TABLE 4. Regression in Thin Melanoma
Regression is frequent in thin melanoma
Focal regression is most common
Criteria and reproducibility of recognizing regression remain
subjective
TABLE 5. Prognostic Factors in Thin Melanoma
Breslow thickness:
<0.76mm—very low risk
>0.76mm—greater risk
Growth phase
Clark level
Mitotic rate
Ulceration
Regression
Lymphatic invasion
Angiotropism of melanoma cells—requires further study in this
thickness category
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that almost all thin melanomas that develop metastases
show a tumor thickness between 0.75 and 1mm.24 There-
fore, we recommend that an upper limit of 0.75mm should
be considered for thin melanomas.
Combinations of adverse risk factors can subdivide the
low-risk stage I group as currently deﬁned. Gimotty et al25
used Breslow thickness with a cutoﬀ of 0.78mm, with
various combinations of Clark level, sex, age, site, and
mitogenicity to identify subgroups with 10-year survival
probabilities ranging from 83% to 99%.
Clark level is no longer required for TNM staging and
accordingly is no longer mentioned in many melanoma
reports. However, it should be emphasized that especially in
thin melanoma Clark level has prognostic signiﬁcance and
should be reported.24,26
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